PTCT PTC Therapeutics
- 43.940
- -1.100-2.44%
- 43.940
- 0.0000.00%
PTC Therapeutics News
Solid Biosciences Stock Jumps 11% Post-market on FDA Update
RBC Capital Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Cuts Target Price to $58
RBC Cuts Price Target on PTC Therapeutics to $58 From $63, Keeps Outperform Rating
Insiders At PTC Therapeutics Sold US$1.2m In Stock, Alluding To Potential Weakness
PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
J.P. Morgan's Top Healthcare Stocks for 2025
Express News | PTC Therapeutics Inc: PTC's Fourth Approval Application Submitted to FDA in 2024
Express News | PTC Therapeutics Announces Vatiquinone Nda Submission to FDA for the Treatment of Children and Adults Living With Friedreich Ataxia
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living With Friedreich Ataxia
Express News | PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Morgan Stanley Upgrades PTC, Cuts Immuneering, Amicus
PTC Therapeutics Raised to Overweight From Equal-Weight by Morgan Stanley
PTC Therapeutics Analyst Ratings
RBC Capital Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $63
PTC Therapeutics (PTCT) Receives a Buy From RBC Capital
Morgan Stanley Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $67
Morgan Stanley Upgrades PTC Therapeutics(PTCT.US) to Buy Rating, Raises Target Price to $67
Raymond James, Cantor Bullish on UniQure Following FDA Update
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
No Data